InvestorsHub Logo
icon url

Mogwai

05/16/16 7:46 PM

#80699 RE: invest2992 #80698

Correct. The only way the trial is getting stopped is if death rate is statistically different between the two arms.
icon url

kenyboy

05/16/16 7:50 PM

#80701 RE: invest2992 #80698

or Stroke incidence in both arms!
icon url

BioChica

05/17/16 9:24 AM

#80725 RE: invest2992 #80698

Well Stroke and MI are also key to success! In addition improvement in lowering of the so called soft MACE, events will be important.

Should see a nice even spread!
icon url

sts66

05/17/16 11:17 AM

#80738 RE: invest2992 #80698

I think MI rate in both groups will be key primary endpoint to look at - with modern ER medical treatments, if you get to the hospital on time you're not likely to have a fatal MI - and JELIS had very few of them. Doesn't matter, since IMO stopping the first MI is the most important thing we need to show - no drug has shown success in stopping the first MI, standalone or as statin add-on.